Skyler Burke
YOU?
Author Swipe
View article: Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study
Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study Open
Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refr…
View article: Atypical Case of Osteomyelitis Pubis due to <i>Corynebacterium striatum</i> in a Patient With End-Stage Renal Disease
Atypical Case of Osteomyelitis Pubis due to <i>Corynebacterium striatum</i> in a Patient With End-Stage Renal Disease Open
We report the case of a 64-year-old woman who presented with progressively worsening right, mid-pelvic pain. Computed tomography images of the abdomen and pelvis were consistent with pubic symphysis osteomyelitis. Open decompression with c…
View article: Atypical Nelson Syndrome Following Right Partial and Left Total Nephrectomy With Incidental Bilateral Total Adrenalectomy of Renal Cell Carcinoma: A Chat Generative Pre-Trained Transformer (ChatGPT)-Assisted Case Report and Literature Review
Atypical Nelson Syndrome Following Right Partial and Left Total Nephrectomy With Incidental Bilateral Total Adrenalectomy of Renal Cell Carcinoma: A Chat Generative Pre-Trained Transformer (ChatGPT)-Assisted Case Report and Literature Review Open
Nelson syndrome (NS) is a dangerous condition that can sometimes manifest after bilateral adrenalectomy (BA), typically in treating Cushing's disease. It is defined by the collection of systemic signs and symptoms that can arise in a state…
View article: Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature
Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature Open
ROS chromosomal rearrangements, which compromise around 1-2% of non-small cell carcinomas, have become an established therapeutic target. While targeted therapy for this mutation usually includes tyrosine kinase inhibitors such as crizotin…